Search results for "Receptor"

showing 10 items of 6990 documents

Association of a single nucleotide polymorphism of RANK gene with blood pressure in Spanish women

2020

Abstract In addition to governing key functions in bone metabolism and the immune system, the RANK/RANKL/OPG system plays a role in the vascular system, particularly in vascular calcification and atherosclerosis. Given that these 2 phenotypes are considered a major cause of high blood pressure (BP), in this study we analyzed the association of SNPs in RANK and OPG genes with blood pressure. An observational study was conducted of 2 SNPs in the RANK gene (rs884205 and rs78326403) and 1 in the OPG gene (rs4876869) with systolic (SBP) and diastolic blood pressure (DBP) in a cohort of 695 women. Data analysis revealed a statistically significant association between the SNP rs884205 and BP press…

medicine.medical_specialty3400Observational StudySingle-nucleotide polymorphismGenome-wide association studyassociation studyPolymorphism Single NucleotidepolymorphismRANK and osteoprotegerin genes03 medical and health sciencessymbols.namesake0302 clinical medicinePolymorphism (computer science)Internal medicineGenotypeHumansMedicineSNP030212 general & internal medicineAlleleReceptor Activator of Nuclear Factor-kappa Bbusiness.industryOsteoprotegerinblood pressureGeneral MedicineMiddle AgedEndocrinologyBonferroni correctionBlood pressureSpain030220 oncology & carcinogenesissymbolsFemalebusinessGenome-Wide Association StudyResearch ArticleMedicine
researchProduct

Effects of endocrine disruptors on genes associated with 17 beta-estradiol metabolism and excretion

2008

International audience; In order to provide a global analysis of the effects of endocrine disruptors on the hormone cellular bioavailability, we combined 17 beta-estradiol (E2) cellular flow studies with real-time PCR and Western blot expression measurements of genes involved in the hormone metabolism and excretion. Three endocrine disruptors commonly found in food were chosen for this study, which was conducted in the estrogen receptor (ER) negative hepatoblastoma HepG2 cell line: bisphenol A (BPA), genistein (GEN) and resveratrol (RES). We showed that 24h after a single dose treatment with genistein, resveratrol or bisphenol A, the expression of ATP-binding cassette transporters (the mult…

medicine.medical_specialtyATP-BINDING CASSETTE TRANSPORTERS[SDV]Life Sciences [q-bio]Clinical BiochemistryBlotting WesternEstrogen receptorGenistein010501 environmental sciencesBiologyPharmacologyResveratrol01 natural sciencesBiochemistryCell LineENDOCRINE DISRUPTORS03 medical and health scienceschemistry.chemical_compoundEndocrinologyInternal medicineUDP-GLUCURONOSYLTRANFERASEmedicineHumansHormone metabolismRNA MessengerMolecular Biology030304 developmental biology0105 earth and related environmental sciencesDNA PrimersPharmacology0303 health sciencesBase SequenceEstradiolReverse Transcriptase Polymerase Chain ReactionMultidrug resistance-associated protein 2Organic ChemistrySULFOTRANSFERASEEndocrinologyEndocrine disruptorchemistryGene Expression Regulation13. Climate actionESTRADIOL METABOLISMMultidrug Resistance-Associated Proteinshormones hormone substitutes and hormone antagonistsHormone
researchProduct

Optimizing the use of linaclotide in patients with constipation-predominant irritable bowel syndrome : an expert consensus report

2017

INTRODUCTION: Irritable bowel syndrome (IBS) is a functional bowel disorder characterized by chronic or recurrent abdominal pain in association with defecation or a change in bowel habits. A predominant disorder of bowel habits, IBS is classified into three main subtypes: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D) and IBS alternating between constipation and diarrhea (IBS-M). Linaclotide is a first-in-class, oral, once-daily guanylate cyclase-C receptor agonist (GC-CA) that is licensed for the symptomatic treatment of moderate-to-severe IBS-C in adults. This review aims to facilitate and optimize clinical practices, establishing common guidelines to monitor patie…

medicine.medical_specialtyAbdominal painAbdominal painConstipationReviewRecommendationsGastroenterologyIrritable Bowel Syndrome03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBloatingGastrointestinal AgentsInternal medicinemedicineHumansPharmacology (medical)030212 general & internal medicineLinaclotideGastroenterologiaIrritable bowel syndromeMedicine(all)business.industryBloatingGastroenterologyIntestins -- MalaltiesGeneral Medicinemedicine.diseaseSíndrome do Intestino IrritávelRheumatologyDiarrheaTreatment OutcomechemistryDefecationLinaclotide030211 gastroenterology & hepatologyPatient managementmedicine.symptomConstipation-predominant irritable bowel syndromebusinessPeptidesReceptors Atrial Natriuretic FactorConstipation
researchProduct

INSAID Variant Classification and Eurofever Criteria Guide Optimal Treatment Strategy in Patients with TRAPS: Data from the Eurofever Registry

2021

Contains fulltext : 231528.pdf (Publisher’s version ) (Closed access) BACKGROUND: TNF receptor-associated periodic syndrome (TRAPS) is a rare autoinflammatory disease caused by dominant mutation of the TNF super family receptor 1A (TNFRSF1A) gene. Data regarding long-term treatment outcomes are lacking. OBJECTIVE: To assess correlations of genotype-phenotypes in patients with TRAPS, as defined by the International Study Group for Systemic Autoinflammatory Diseases (INSAID) classification and Eurofever criteria, with treatment responses. METHODS: Data from 226 patients with variants of the TNFRSF1A gene and enrolled in the Eurofever registry were classified according to the INSAID classifica…

medicine.medical_specialtyAbdominal painAutoinflammatory diseasesGroup AGroup BAA amyloidosis Anakinra Autoinflammatory diseases Colchicine TRAPS Abdominal Pain Colchicine FemaleHumans Mutation Registries Hereditary Autoinflammatory Diseases03 medical and health sciences0302 clinical medicineSettore MED/38 - Pediatria Generale E SpecialisticaAA amyloidosisTNF receptor-associated periodic syndrome (TRAPS) ; TNFRSF1A geneInternal medicinemedicineAA amyloidosisHumansImmunology and AllergyIn patientRegistries030212 general & internal medicineLikely pathogenicAnakinrabusiness.industryHereditary Autoinflammatory DiseasesTRAPSmedicine.diseaseAbdominal PainAnakinra030228 respiratory systemTNF receptor associated periodic syndromeMutationFemalemedicine.symptombusinessColchicineAA amyloidosis; Anakinra; Autoinflammatory diseases; Colchicine; TRAPSInflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5]medicine.drug
researchProduct

Topical application of the adenosine A2Areceptor agonist CGS-21680 prevents phorbol-induced epidermal hyperplasia and inflammation in mice

2014

The nucleoside adenosine is a known regulator of immunity and inflammation that mediates, at least in part, the anti-inflammatory effect of methotrexate, an immunosuppressive agent widely used to treat autoimmune inflammatory diseases. Adenosine A2A receptors play a key role in the inhibition of the inflammatory process besides promoting wound healing. Therefore, we aimed to determine the topical effect of a selective agonist, CGS-21680, on a murine model of skin hyperplasia with a marked inflammatory component. Pretreatment with either CGS-21680 (5 μg per site) or the reference agent dexamethasone (200 μg/site) prevented the epidermal hyperplasia and inflammatory response induced by topica…

medicine.medical_specialtyAdenosineAdenosine A2 Receptor AgonistsAdministration Topicalmedicine.medical_treatmentAnti-Inflammatory AgentsAdenosine A2A receptorInflammationDermatologyPharmacologyBiologySkin DiseasesBiochemistryDexamethasoneMicechemistry.chemical_compoundInternal medicinePhenethylaminesmedicineAnimalsMolecular BiologyDexamethasoneCell ProliferationPeroxidaseCGS-21680InflammationHyperplasiaAdenosineAdenosine receptorDisease Models AnimalEndocrinologyCytokinechemistryCytokinesTetradecanoylphorbol AcetateFemaleCollagenEpidermismedicine.symptomWound healingmedicine.drugExperimental Dermatology
researchProduct

Characterization of adenosine receptors in guinea-pig isolated left atria

1989

1. The effects of purinergic stimulation on action potential, force of contraction, 86Rb efflux and 45Ca uptake were investigated in guinea-pig left atria. 2. Adenosine exerted a negative inotropic effect which was antagonized by adenosine deaminase but enhanced by dipyridamole. 3. The negative inotropic effect of adenosine was mimicked by 5'-(N-ethyl)-carboxamido-adenosine (NECA) and the isomers of N6-(phenyl-isopropyl)-adenosine, R-PIA and S-PIA. NECA and R-PIA were about 100 times more potent than adenosine, whereas R-PIA was about 100 times more potent than S-PIA. 4. The inotropic effects of adenosine (in the presence of dipyridamole), NECA, R-PIA and S-PIA were competitively antagonize…

medicine.medical_specialtyAdenosineContraction (grammar)Guinea PigsPopulationAction PotentialsStimulationAdenosine-5'-(N-ethylcarboxamide)In Vitro TechniquesMembrane PotentialsAdenosine deaminaseTheophyllineInternal medicinemedicineAnimalseducationPharmacologyMembrane potentialeducation.field_of_studybiologyChemistryCalcium RadioisotopesMyocardiumPurinergic receptorReceptors PurinergicHeartDipyridamoleMyocardial ContractionAdenosineAdenosine receptorElectric StimulationEndocrinologyPhenylisopropyladenosinecardiovascular systembiology.proteinRubidium RadioisotopesResearch Articlemedicine.drugBritish Journal of Pharmacology
researchProduct

Adrenoceptor-mediated effects on calcium channel currents are antagonized by 5?-(N-ethyl)-carboxamido-adenosine in guinea-pig atrial cells

1992

In guinea-pig atrial myocytes, the effects of the adenosine analogue 5′-(N-ethyl)-carboxamido-adenosine (NECA) in the presence of isoprenaline (ISO) on Ca2+ channel activity were analyzed. Single Ca2+ channel currents were recorded from cell-attached patches by application of several hundred 100 ms depolarizing steps. Under control conditions, burstlike activity of channel openings during some depolarizing steps were followed by variably long periods of quiescence (blank sweeps). During superfusion with ISO (100 nmol/l), ensemble-averaged (mean) current was increased by about 150%. The underlying mechanism was found to be a significant increase in the channel availability, defined as the ra…

medicine.medical_specialtyAdenosineGuinea Pigschemistry.chemical_elementStimulationAdenosine-5'-(N-ethylcarboxamide)In Vitro TechniquesCalciumInternal medicineIsoprenalinemedicineAnimalsHeart AtriaPharmacologyChemistryCalcium channelPurinergic receptorIsoproterenolDepolarizationGeneral MedicineAdenosine receptorAdenosineReceptors AdrenergicPerfusionEndocrinologyCalcium Channelsmedicine.drugNaunyn-Schmiedeberg's Archives of Pharmacology
researchProduct

?-Carboline binding indicates the presence of benzodiazepine receptor subclasses in the bovine central nervous system

1982

Receptor binding studies were performed with tritiated propyl β-carboline-3-carboxylate ([3H]PrCC), tritiated ethyl β-carboline-3-carboxylate ([3H]ECC), and tritiated flunitrazepam ([3H]FNT) in membrane preparations from different regions of the bovine brain and retina. Specific binding in all regions investigated was associated with benzodiazepine receptor sites. However, not all benzodiazepine receptor sites. However, not all benzodiazepine receptors in the regions investigated as determined by the specific binding of tritiated flunitrazepam ([3H]FNT) are available for [3H]PrCC suggesting that specific [3H]PrCC binding labels only one subclass or subpopulation of the benzodiazepine recept…

medicine.medical_specialtyAdenosineIndolesmedicine.drug_classReceptors DrugCentral nervous systemHippocampusSubstrate Specificitychemistry.chemical_compoundInternal medicinemedicineAnimalsReceptorgamma-Aminobutyric AcidBrain ChemistryPharmacologyBenzodiazepineBinding SitesGABAA receptorChemistrybeta-CarbolineGeneral MedicineReceptors GABA-Amedicine.anatomical_structureEndocrinologyGABAergicCattleFlunitrazepamCarbolinesmedicine.drugNaunyn-Schmiedeberg's Archives of Pharmacology
researchProduct

Adenosine receptor agonists for promotion of dermal wound healing

2008

Wound healing is a dynamic and complex process that involves a well-coordinated, highly regulated series of events including inflammation, tissue formation, revascularization and tissue remodeling. However, this orderly sequence is impaired in certain pathophysiological conditions such as diabetes mellitus, venous insufficiency, chronic glucocorticoid use, aging and malnutrition. Together with proper wound care, promotion of the healing process is the primary objective in the management of chronic poorly healing wounds. Recent studies have demonstrated that A(2A) adenosine receptor agonists promote wound healing in normal and diabetic animals and one such agonist, Sonedenoson, is currently …

medicine.medical_specialtyAdenosineNeovascularization PhysiologicInflammationBioinformaticsBiochemistrySkin DiseasesArticle03 medical and health sciencesWound care0302 clinical medicineInternal medicinemedicinePurinergic P1 Receptor AgonistsAnimalsHumans030304 developmental biology2. Zero hungerPharmacology0303 health sciencesWound Healingbusiness.industryReceptors Purinergic P1Granulation tissuemedicine.diseaseAdenosineAdenosine receptorDiabetic footDiabetic Foot3. Good healthDiabetic foot ulcermedicine.anatomical_structureEndocrinology030220 oncology & carcinogenesismedicine.symptomWound healingbusinessmedicine.drug
researchProduct

Adrenergic modulation of astroglial phospholipase D activity and cell proliferation.

1999

As phospholipase D (PLD) activation has been associated with mitogenic signalling in several cell types, we tested an association between adrenergic activation of PLD and cellular proliferation in primary cultures of rat cortical astrocytes. In 2-week old cultures, PLD activation by noradrenaline (EC50: 0.49 microM) was inhibited by prazosin, a specific antagonist at alpha1-adrenergic receptors (IC50: 0.23 microM). Adrenergic PLD activation was not affected by genistein, an inhibitor of tyrosine kinases, or by Ro 31-8220, an inhibitor of protein kinase C (PKC), but was dose-dependently depressed in the presence of brefeldin A (1-100 microg/ml), an inhibitor of ARF activation. In experiments…

medicine.medical_specialtyAdrenergic AntagonistsAdrenergicBiologyPharmacologychemistry.chemical_compoundNorepinephrineGTP-Binding ProteinsIsoprenalineInternal medicinemedicineAdrenergic antagonistPrazosinPhospholipase DPhospholipase D activityAnimalsMolecular BiologyProtein kinase CCells CulturedBrefeldin APhospholipase DGeneral NeurosciencePrazosinBrefeldin AAdrenergic AgonistsPropranololRatsReceptors AdrenergicEndocrinologychemistryAlcoholsAstrocyteslipids (amino acids peptides and proteins)Neurology (clinical)Cell DivisionDevelopmental Biologymedicine.drugSignal TransductionBrain research
researchProduct